GH Secretagogues - RESEARCH DATA
Ipamorelin
Molecular Weight
711.9 Da
Half-Life
~2 hours
Peptide Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
GH RELEASEGHRPSELECTIVEANTI-AGING
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist (GHSR-1a). Unlike other GHRPs, ipamorelin demonstrates high selectivity for GH release without significant cortisol, prolactin, or ACTH stimulation.
Its clean GH pulse profile and favorable safety data in clinical studies make it one of the most widely researched GHRPs. It is often combined with CJC-1295 to produce sustained GH elevation.
Deeper Analysis
## Mechanism of Action
Ipamorelin mimics ghrelin and binds selectively to the GHSR-1a receptor in the pituitary, triggering pulsatile GH release. Its selectivity profile means minimal activation of cortisol or prolactin pathways, distinguishing it from GHRP-2 and GHRP-6.
## Research Highlights
- Dose-dependent GH release in phase I clinical trials
- No significant effect on cortisol, ACTH, or prolactin at therapeutic doses
- Improved bone density in rodent models
- Synergistic effect with CJC-1295 for prolonged GH elevation
## Dosing Notes (Research Context Only)
Typical dosing: 100-300 mcg administered 2-3x daily subcutaneously. Commonly used pre-sleep and post-workout for pulse alignment.
## Half-Life & Stability
Short half-life (~2 hours), necessitating multiple daily administrations or combination with long-acting GHRH analogs.
Peer-Reviewed Citations
Members-only content
Connect your Solana wallet to unlock full research articles, dosing protocols, stack guides, and community forum access.
No NFT required - Wallet signature only - Free access